Biomarker Landscape of Antibody Drug Conjugates (ADCs) and Bispecific Antibodies in Clinical Trials for Lung Cancer
Clin Lung Cancer
.
2024 Oct 31:S1525-7304(24)00222-5.
doi: 10.1016/j.cllc.2024.10.008.
Online ahead of print.
Authors
Madhan Srinivasan Kumar
1
,
Sameer Deshmukh
2
,
Charmi Bhanushali
1
,
Yanis Boumber
2
,
Johnathan Riess
3
,
Abdul Rafeh Naqash
4
,
Vivek Subbiah
5
,
Aakash Desai
6
Affiliations
1
Department of Medicine, Saint Vincent Hospital, Worcester, MA, USA.
2
Division of Hematology and Oncology, Department of Medicine, University of Alabama at Birmingham, AL, USA.
3
Division of Hematology and Oncology, UC Davis Medical Center, Sacramento, CA, USA.
4
Stephenson Cancer Center, University of Oklahoma, OK, USA.
5
Sarah Cannon Research Institute, Nashville, TN, USA.
6
Division of Hematology and Oncology, Department of Medicine, University of Alabama at Birmingham, AL, USA. Electronic address:
[email protected]
.
PMID:
39592292
DOI:
10.1016/j.cllc.2024.10.008
No abstract available
Keywords:
ADC; Antibody Drug Conjugates; Bispecific Antibodies; BsAb; Clinical trials; Lung Cancer.
Publication types
Case Reports